Open AccessThis article is
- freely available
Clinical Management of HIV Drug Resistance
HIV Drug Resistance Program, NCI, NIH, Building 10 Rm 5A06, Bethesda, MD 20892, USA
* Author to whom correspondence should be addressed.
Received: 9 March 2011; in revised form: / Accepted: 30 March 2011 / Published: 14 April 2011
Abstract: Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. Management of clinical drug resistance requires in depth evaluation, and includes extensive history, physical examination and laboratory studies. Appropriate use of resistance testing provides valuable information useful in constructing regimens for treatment-experienced individuals with viremia during therapy. This review outlines the emergence of drug resistance in vivo, and describes clinical evaluation and therapeutic options of the individual with rebound viremia during therapy.
Keywords: HIV; drug resistance testing; clinical management
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Cortez, K.J.; Maldarelli, F. Clinical Management of HIV Drug Resistance. Viruses 2011, 3, 347-378.
Cortez KJ, Maldarelli F. Clinical Management of HIV Drug Resistance. Viruses. 2011; 3(4):347-378.
Cortez, Karoll J.; Maldarelli, Frank. 2011. "Clinical Management of HIV Drug Resistance." Viruses 3, no. 4: 347-378.